PFE - Pfizer Inc.
44.20 -0.17 (-0.38%)
After hours: 6:05PM EDT
| Previous close | 44.50 |
| Open | 44.44 |
| Bid | 44.21 x 4000 |
| Ask | 44.50 x 1000 |
| Day's range | 44.02 - 44.51 |
| 52-week range | 33.20 - 45.81 |
| Volume | 17,103,310 |
| Avg. volume | 20,844,756 |
| Market cap | 260.102B |
| Beta (3Y monthly) | 0.84 |
| PE ratio (TTM) | 11.85 |
| EPS (TTM) | 3.74 |
| Earnings date | 30 Oct 2018 |
| Forward dividend & yield | 1.36 (3.06%) |
| Ex-dividend date | 2018-11-08 |
| 1y target est | 42.94 |
- Zacks•1 hour ago
Pfizer (PFE) Stock Moves -0.29%: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $44.37, marking a -0.29% move from the previous day.
- Market Realist•5 hours ago
Pfizer: Analysts’ Recommendations on October 22
Analysts expect Pfizer’s (PFE) top line to increase ~2.9% to ~$13.5 billion during the third quarter. The company’s EPS is expected to increase to $0.75 in the third quarter—compared to $0.67 in the third quarter of 2017.
- Market Realist•6 hours ago
Pfizer: Analysts Expect Revenue Growth in Q3
As we discussed earlier, analysts expect Pfizer’s (PFE) revenues to be ~$13.5 billion in the third quarter—which is ~2.8% growth compared to revenues of $13.2 billion during the third quarter of 2017. The revenue growth is expected to be driven by innovative health products’ strong performance.
- Market Realist•6 hours ago
Pfizer’s Third-Quarter Earnings: Analysts’ Estimates
Pfizer (PFE), one of the leading pharmaceutical companies, is scheduled to release its third-quarter earnings on October 30. For the third quarter, analysts expect Pfizer to report an EPS of $0.75 on revenues of $13.5 billion.
- Market Realist•3 days ago
What’s Pfizer’s Current Valuation?
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
- Market Realist•3 days ago
Pfizer’s Dividends and Earnings Quality
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
- Market Realist•3 days ago
Pfizer Reported Revenue Growth in Global Markets
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
- Market Realist•4 days ago
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
- Market Realist•4 days ago
What Are Pfizer’s Revenue Drivers?
Pfizer (PFE) reported revenues of $13.5 billion during the second quarter—4% revenue growth YoY compared to $12.9 million during the second quarter of 2017. The revenues are expected to increase 2.8% to $13.5 billion during the third quarter.
- Market Realist•4 days ago
Novartis Missed Revenue Estimates in Q3 2018
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
- Market Realist•4 days ago
Pfizer’s Market Cap and Shareholding Pattern
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
- Market Realist•4 days ago
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
- Motley Fool•5 days ago
Is Sangamo Therapeutics Inc. a Buy?
Can this beaten-down gene-editing and gene therapy biotech bounce back?
- Motley Fool•5 days ago
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
- Zacks•5 days ago
Top Research Reports for Pfizer, Caterpillar & Charter Communications
Top Research Reports for Pfizer, Caterpillar & Charter Communications
- Zacks•6 days ago
Pfizer (PFE) Gains But Lags Market: What You Should Know
In the latest trading session, Pfizer (PFE) closed at $43.92, marking a +1.86% move from the previous day.
- Yahoo Finance•6 days ago
Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
Market Realist•6 days agoWhat Nektar Therapeutics’ Valuation Trend Indicates
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
Market Realist•6 days agoAnalyzing Nektar Therapeutics’ Operational Performance
Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.
- Zacks•6 days ago
Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?
Style Box ETF report for FTCS
Market Realist•6 days agoHow Analysts View Merck Stock, Pre-Q3 Results
Between October 11 and 12, Merck (MRK) stock rose ~2.11% from $68.37 to close at $69.81. It was 32% higher than its 52-week low of $52.83 on April 3. Merck’s 52-week high is $72.89, reached on October 10.
Associated Press•7 days agoUS wants drug prices in TV ads: 'Patients deserve to know'
TRENTON, N.J. (AP) — The federal government said Monday that it wants to force drugmakers to disclose prices for prescription medicines in their TV commercials.
Bloomberg•7 days agoTrump's Drug-Ad Price Shaming Won't Fix the Problem
A series of tweets earlier this year managed to push pharmaceutical companies including Pfizer Inc. to temporarily halt price increases. Donald J. Trump @realDonaldTrump Pfizer & others should be ashamed that they have raised drug prices for no reason. The tactic is being taken to a new level with the administration’s plan, officially revealed Monday afternoon by Health and Human Services Secretary Alex Azar, to force drugmakers to disclose the list price of medicines available under Medicare or Medicaid in their TV ads. The main issue with the proposed rule is that a drug’s list or sticker price is very far from what many people or their health-care plans actually pay.
Market Realist•7 days agoMerck’s Operating Expenditure and Recent Developments
Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.
- Market Realist•7 days ago
What’s Expected for Merck’s Q3 2018 Earnings
Analysts expect Merck (MRK) to report GAAP net income of $2.23 billion and GAAP EPS of $0.83 in the third quarter of 2018. In Q2 2018, the company’s GAAP net income fell YoY (year-over-year) from $1.9 billion to $1.7 billion, and its GAAP EPS fell YoY from $0.71 to $0.63. Merck’s non-GAAP net income grew ~3% YoY in Q2 2018, to $2.9 billion from $2.8 billion, and its non-GAAP EPS grew ~5% YoY from $1.01 to $1.06.
